fluvoxamine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
1230 54739-18-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • fluvoxamine
  • fluvoxamine maleate
  • depromel
A selective serotonin reuptake inhibitor that is used in the treatment of DEPRESSION and a variety of ANXIETY DISORDERS.
  • Molecular weight: 318.34
  • Formula: C15H21F3N2O2
  • CLOGP: 3.03
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 1
  • TPSA: 56.84
  • ALOGS: -4.64
  • ROTB: 10

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.10 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 14.87 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 2 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 13.46 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 53 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 23.50 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 31.95 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.20 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 12.50 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Dec. 5, 1994 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Toxicity to various agents 198.51 60.09 58 339 32696 2324992
Drug interaction 151.44 60.09 46 351 29117 2328571
Completed suicide 134.26 60.09 39 358 20995 2336693
Serotonin syndrome 101.68 60.09 22 375 3518 2354170
Intentional self-injury 98.32 60.09 22 375 4105 2353583
Suicide attempt 90.02 60.09 25 372 11257 2346431
Intentional overdose 71.81 60.09 21 376 11300 2346388
Depression 67.54 60.09 25 372 28107 2329581
Schizophrenia 65.52 60.09 13 384 1346 2356342
Electrocardiogram QT prolonged 65.34 60.09 18 379 7796 2349892
Anxiety 62.86 60.09 24 373 29335 2328353

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Completed suicide 132.15 46.55 41 366 16271 1730103
Toxicity to various agents 131.37 46.55 47 360 29094 1717280
Serotonin syndrome 122.68 46.55 27 380 2761 1743613
Drug interaction 85.12 46.55 34 373 27924 1718450
Schizophrenia 79.86 46.55 18 389 2028 1744346
Obsessive-compulsive disorder 65.10 46.55 13 394 815 1745559
Drug ineffective 63.81 46.55 36 371 63765 1682609
Cardio-respiratory arrest 60.88 46.55 20 387 9273 1737101
Condition aggravated 51.44 46.55 22 385 21128 1725246
Overdose 49.44 46.55 20 387 16681 1729693
Intentional overdose 48.14 46.55 16 391 7654 1738720
Akathisia 48.05 46.55 11 396 1317 1745057

Pharmacologic Action:

SourceCodeDescription
ATC N06AB08 NERVOUS SYSTEM
PSYCHOANALEPTICS
ANTIDEPRESSANTS
Selective serotonin reuptake inhibitors
CHEBI has role CHEBI:50949 serotonin uptake inhibitor
CHEBI has role CHEBI:35474 anxiolytic drug
CHEBI has role CHEBI:35469 antidepressant
MeSH PA D014151 Anti-Anxiety Agents
MeSH PA D000928 Antidepressive Agents
MeSH PA D018687 Antidepressive Agents, Second-Generation
MeSH PA D002491 Central Nervous System Agents
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D065609 Cytochrome P-450 CYP1A2 Inhibitors
MeSH PA D065689 Cytochrome P-450 CYP2C19 Inhibitors
MeSH PA D065607 Cytochrome P-450 Enzyme Inhibitors
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D049990 Membrane Transport Modulators
MeSH PA D065606 Metabolic Side Effects of Drugs and Substances
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D014179 Neurotransmitter Uptake Inhibitors
MeSH PA D011619 Psychotropic Drugs
MeSH PA D018490 Serotonin Agents
MeSH PA D017367 Serotonin Uptake Inhibitors
FDA EPC N0000175696 Serotonin Reuptake Inhibitor
MeSH PA D014149 Tranquilizing Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Social phobia indication 25501002 DOID:11257
Obsessive-compulsive disorder indication 191736004 DOID:10933
Depressive disorder off-label use 35489007
Posttraumatic stress disorder off-label use 47505003 DOID:2055
Bipolar affective disorder, current episode depression off-label use 191627008 DOID:3312
Suicidal thoughts contraindication 6471006
Bipolar disorder contraindication 13746004 DOID:3312
Neuroleptic malignant syndrome contraindication 15244003 DOID:14464
Upper gastrointestinal hemorrhage contraindication 37372002
Syndrome of inappropriate vasopressin secretion contraindication 55004003 DOID:3401
Blood coagulation disorder contraindication 64779008 DOID:1247
Epilepsy contraindication 84757009 DOID:1826
Hyponatremia contraindication 89627008
Mania contraindication 231494001
Hypomania contraindication 231496004
Disease of liver contraindication 235856003 DOID:409
Serotonin syndrome contraindication 371089000
Breastfeeding (mother) contraindication 413712001
Poor metabolizer due to cytochrome p450 CYP2D6 variant contraindication 423629005
Smokes tobacco daily contraindication 449868002

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.36 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
100MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** LUVOX CR JAZZ PHARMS N022033 Feb. 28, 2008 DISCN CAPSULE, EXTENDED RELEASE ORAL 7465462 May 10, 2020 TREATMENT OF OBSESSIVE COMPULSIVE DISORDER TREATABLE WITH AN SSRI
150MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** LUVOX CR JAZZ PHARMS N022033 Feb. 28, 2008 DISCN CAPSULE, EXTENDED RELEASE ORAL 7465462 May 10, 2020 TREATMENT OF OBSESSIVE COMPULSIVE DISORDER TREATABLE WITH AN SSRI

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Sodium-dependent serotonin transporter Transporter INHIBITOR Ki 8.51 WOMBAT-PK CHEMBL
Sodium-dependent dopamine transporter Transporter Ki 8.84 CHEMBL
Sigma non-opioid intracellular receptor 1 Membrane receptor Ki 7.44 CHEMBL
Cytochrome P450 1A2 Enzyme Ki 5.07 WOMBAT-PK
Sodium-dependent noradrenaline transporter Transporter Ki 5.95 PDSP
Sigma non-opioid intracellular receptor 1 Membrane receptor Ki 7.44 CHEMBL
Sodium-dependent serotonin transporter Transporter INHIBITOR Ki 8.19 IUPHAR

External reference:

IDSource
4023976 VUID
N0000021981 NUI
C0085228 UMLSCUI
D00824 KEGG_DRUG
5LGN83G74V UNII
61718-82-9 SECONDARY_CAS_RN
96213009 SNOMEDCT_US
4023976 VANDF
003633 NDDF
42355 RXNORM
d03804 MMSL
372905008 SNOMEDCT_US
CHEMBL814 ChEMBL_ID
CHEMBL1409 ChEMBL_ID
DB00176 DRUGBANK_ID
3879 INN_ID
FVX PDB_CHEM_ID
CHEBI:5138 CHEBI
5324346 PUBCHEM_CID
D016666 MESH_DESCRIPTOR_UI
7189 IUPHAR_LIGAND_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Fluvoxamine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 0228-2848 CAPSULE, EXTENDED RELEASE 100 mg ORAL ANDA 20 sections
Fluvoxamine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 0228-2849 CAPSULE, EXTENDED RELEASE 150 mg ORAL ANDA 20 sections
Fluvoxamine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 0378-0407 TABLET, FILM COATED 25 mg ORAL ANDA 20 sections
Fluvoxamine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 0378-0412 TABLET, FILM COATED 50 mg ORAL ANDA 20 sections
Fluvoxamine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 0378-0414 TABLET, FILM COATED 100 mg ORAL ANDA 20 sections
Fluvoxamine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 0615-7569 TABLET, FILM COATED 100 mg ORAL ANDA 20 sections
Fluvoxamine maleate HUMAN PRESCRIPTION DRUG LABEL 1 0832-1670 TABLET, FILM COATED 25 mg ORAL ANDA 20 sections
Fluvoxamine maleate HUMAN PRESCRIPTION DRUG LABEL 1 0832-1671 TABLET, FILM COATED 50 mg ORAL ANDA 20 sections
Fluvoxamine maleate HUMAN PRESCRIPTION DRUG LABEL 1 0832-1672 TABLET, FILM COATED 100 mg ORAL ANDA 20 sections
Fluvoxamine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 10370-175 CAPSULE, EXTENDED RELEASE 100 mg ORAL ANDA 20 sections
Fluvoxamine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 10370-176 CAPSULE, EXTENDED RELEASE 150 mg ORAL ANDA 20 sections
Fluvoxamine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 16590-270 TABLET 25 mg ORAL NDA 11 sections
fluvoxamine maleate HUMAN PRESCRIPTION DRUG LABEL 1 33261-683 TABLET, COATED 50 mg ORAL NDA AUTHORIZED GENERIC 21 sections
Fluvoxamine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 60505-0164 TABLET 25 mg ORAL ANDA 20 sections
Fluvoxamine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 60505-0165 TABLET 50 mg ORAL ANDA 20 sections
Fluvoxamine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 60505-0166 TABLET 100 mg ORAL ANDA 20 sections
fluvoxamine maleate HUMAN PRESCRIPTION DRUG LABEL 1 62559-158 TABLET, COATED 25 mg ORAL NDA authorized generic 20 sections
fluvoxamine maleate HUMAN PRESCRIPTION DRUG LABEL 1 62559-159 TABLET, COATED 50 mg ORAL NDA authorized generic 20 sections
fluvoxamine maleate HUMAN PRESCRIPTION DRUG LABEL 1 62559-160 TABLET, COATED 100 mg ORAL NDA authorized generic 20 sections
fluvoxamine maleate HUMAN PRESCRIPTION DRUG LABEL 1 63629-8018 TABLET, COATED 25 mg ORAL NDA authorized generic 21 sections
fluvoxamine maleate HUMAN PRESCRIPTION DRUG LABEL 1 68151-0637 TABLET, COATED 50 mg ORAL NDA authorized generic 21 sections
fluvoxamine maleate HUMAN PRESCRIPTION DRUG LABEL 1 68788-7219 TABLET, COATED 100 mg ORAL NDA authorized generic 21 sections
fluvoxamine maleate HUMAN PRESCRIPTION DRUG LABEL 1 70518-1057 TABLET, COATED 100 mg ORAL NDA authorized generic 21 sections
fluvoxamine maleate HUMAN PRESCRIPTION DRUG LABEL 1 70518-1643 TABLET, COATED 50 mg ORAL NDA authorized generic 21 sections
fluvoxamine maleate HUMAN PRESCRIPTION DRUG LABEL 1 70518-1789 TABLET, COATED 25 mg ORAL NDA authorized generic 21 sections
fluvoxamine maleate HUMAN PRESCRIPTION DRUG LABEL 1 71335-0264 TABLET, COATED 100 mg ORAL NDA authorized generic 20 sections